Atherothrombosis and the role of antiplatelet therapy

Steg, Philippe Gabriel; Dorman, Stephen; Amarenco, Pierre

doi:10.1111/j.1538-7836.2011.04277.x

Cited by 23 publications

(26 citation statements)

References 72 publications

(64 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A newer agent, prasugrel, has a faster onset and more inhibition of platelets than clopidogrel. 26 These pharmacodynamics are favorable for potential use in endovascular therapy with partial recanalization or as an adjunctive agent to mechanical or fibrinolytic local AIS therapy. Stent implantation necessitates periprocedure antiplatelet therapy to reduce the risk of acute and delayed stent thrombosis.…”

Section: Figure 1 Platelet Aggregation and Antiplatelet Medication Inmentioning

confidence: 99%

“…The mechanism of action of aspirin is well known to be related to thromboxane A2 and Cox I. 26 Aspirin offers a small but significant reduc- Selected intra-arterial thrombolysis studies reporting the use of adjunctive antithrombotic agents Lee et al 14 Deshmukh et al 16 Mangiafico et al 17 Qureshi et al 15 No. of patients 26 Abbreviations: IA ϭ intra-arterial; ICH ϭ intracranial hemorrhage.…”

Section: Figure 1 Platelet Aggregation and Antiplatelet Medication Inmentioning

confidence: 99%

“…It is a more selective phosphodiesterase type III inhibitor, and similar to dipyridamole, there is a vasodilatory effect. 26 These phosphodiesterase inhibitors have demonstrated efficacy in secondary stroke prevention; however, their role in acute endovascular therapy has not been shown. DISCUSSION There are limited data on the role for adjunctive antithrombotic therapy in endovascular management of AIS and there are no guidelines on the use of these therapies.…”

Section: Figure 1 Platelet Aggregation and Antiplatelet Medication Inmentioning

confidence: 99%

See 2 more Smart Citations

Multimodal endovascular reperfusion therapies

Lazzaro

Zaidat²

2012

Neurology

View full text Add to dashboard Cite

Pharmacologic and mechanical endovascular acute ischemic stroke therapy aims to recanalize occluded cerebral vessels to achieve improved clinical outcome. Several limitations to achieving this goal have been identified; one of the least discussed challenges in the literature is reocclusion. The intraprocedure and periprocedural roles of anticoagulation and antiplatelet agents in preventing reocclusion are unclear. In this review, the role of antiplatelet and anticoagulation agents as an adjunctive to acute ischemic stroke endovascular revascularization therapy is discussed.

show abstract

Section: Figure 1 Platelet Aggregation and Antiplatelet Medication Inmentioning

confidence: 99%

Section: Figure 1 Platelet Aggregation and Antiplatelet Medication Inmentioning

confidence: 99%

Section: Figure 1 Platelet Aggregation and Antiplatelet Medication Inmentioning

confidence: 99%

See 1 more Smart Citation

Multimodal endovascular reperfusion therapies

Lazzaro

Zaidat²

2012

Neurology

View full text Add to dashboard Cite

show abstract

“…These risk factors are similar across the various arterial beds affected. Hence, many patients have silent or clinically overt disease at two or more sites 14 . The International Reduction of Atherothrombosis for Continued Health (REACH) registry has shown that 25% of patients with coronary artery disease, 40% with cerebrovascular disease, and 62% with peripheral artery disease 15 have clinically overt systemic disease 16 .…”

Section: Platelets and Atherothrombosismentioning

confidence: 99%

Platelets, atherothrombosis, and atherosclerosis

Egan

Áinle

Kenny

2016

Preprint

View full text Add to dashboard Cite

Cardiovascular disease is the leading cause of morbidity and mortality worldwide. In 2008 alone, 17.3 million deaths (representing 30% of all deaths) were attributable to the complications of cardiovascular disease. Of these deaths, 7.3 million were due to coronary artery disease while 6.2 million were attributable to stroke. Cardiovascular disease is expected to remain the leading cause of death globally, with the number of deaths expected to reach 23.6 million annually by 2030 (WHO statistics, 2012). Vascular disease arises through the complications of atherosclerosis, a complex chronic inflammatory condition affecting the arterial circulation. It leads to the development of vascular lesions or atherosclerotic plaques, which manifest as asymmetrical thickenings of the intima of medium to large sized elastic and muscular arteries. Arterial thrombosis on ruptured atherosclerotic plaques can lead to acute events, such as myocardial infarction (MI) and ischemic stroke. Platelets are the key cellular component of arterial thrombi with platelet adhesion under high shear conditions being central to atherothrombosis. In addition, platelets play a role in the progression of atherosclerosis. In this review, we will discuss the evidence for the role of platelets in atherothrombosis, notably the efficacy of antiplatelet agents in the prevention of ischemic events, and finally their role in the progression of atherosclerosis (atherogenesis).

show abstract

“…[1][2][3] The use of antiplatelet agents has proven beneficial and is supported by the American College of Cardiology Foundation/American Heart Association guidelines for secondary prevention of atherothrombosis and the guidelines for patients with unstable angina/non-ST-segment elevation myocardial infarction (MI). 2,4 The use of thienopyridines (clopidogrel and prasugrel) and nonthienopyridines (ticagrelor) to antagonize P2Y 12 receptors on the surface of platelets helps reduce the risk of ischemic events and is recommended in the setting of acute coronary syndrome (ACS) and percutaneous coronary interventions (PCIs).…”

mentioning

confidence: 99%